Dimitra Gika

Summary

Affiliation: University of Athens
Country: Greece

Publications

  1. ncbi request reprint Pathogenesis and treatment of renal failure in multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leukemia 22:1485-93. 2008
  2. pmc Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
    Evangelos Terpos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra University Hospital, Athens, Greece
    Onco Targets Ther 6:531-8. 2013
  3. ncbi request reprint Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
    Meletios Dimopoulos
    Department of Clinical Therapeutics, University of Athens, Athens, Greece Electronic address
    Lancet Oncol 14:1129-40. 2013
  4. pmc Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperat
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    BMC Cancer 13:163. 2013
  5. doi request reprint How lenalidomide is changing the treatment of patients with multiple myeloma
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
    Crit Rev Oncol Hematol 88:S23-35. 2013
  6. pmc Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Haematologica 98:1264-72. 2013
  7. doi request reprint Proteasome inhibitor therapy for Waldenström's macroglobulinemia
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece
    Clin Lymphoma Myeloma Leuk 13:235-7. 2013
  8. pmc Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
    Meletios A Dimopoulos
    University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
    Haematologica 98:784-8. 2013
  9. doi request reprint The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leukemia 27:423-9. 2013
  10. doi request reprint Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Eur J Haematol 89:10-5. 2012

Detail Information

Publications155 found, 100 shown here

  1. ncbi request reprint Pathogenesis and treatment of renal failure in multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leukemia 22:1485-93. 2008
    ....
  2. pmc Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
    Evangelos Terpos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra University Hospital, Athens, Greece
    Onco Targets Ther 6:531-8. 2013
    ..This paper reviews the chemistry and mechanisms of action of pomalidomide as well as all the available data from clinical trials on pomalidomide use in patients with refractory/relapsed multiple myeloma...
  3. ncbi request reprint Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
    Meletios Dimopoulos
    Department of Clinical Therapeutics, University of Athens, Athens, Greece Electronic address
    Lancet Oncol 14:1129-40. 2013
    ..We aimed to assess efficacy and tolerability of vorinostat in combination with bortezomib for treatment of patients with relapsed or refractory multiple myeloma...
  4. pmc Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperat
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    BMC Cancer 13:163. 2013
    ..Limited information exists on the relationship of HER2/TOP2A gene status in the presence of centromere 17 (CEP17) gain with outcome of patients treated with anthracycline-containing adjuvant chemotherapy...
  5. doi request reprint How lenalidomide is changing the treatment of patients with multiple myeloma
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
    Crit Rev Oncol Hematol 88:S23-35. 2013
    ..As the paradigm of myeloma disease continues to change, future studies will determine the efficacy of lenalidomide in novel combinations with potentially complimentary agents. ..
  6. pmc Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Haematologica 98:1264-72. 2013
    ..1 months. These findings suggest bortezomib-dexamethasone represents an active, feasible second-line treatment option for patients with relapsed/refractory myeloma. ..
  7. doi request reprint Proteasome inhibitor therapy for Waldenström's macroglobulinemia
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece
    Clin Lymphoma Myeloma Leuk 13:235-7. 2013
    ..Second generation PIs, such as carfilzomib, are also promising but further investigation is needed...
  8. pmc Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
    Meletios A Dimopoulos
    University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
    Haematologica 98:784-8. 2013
    ..Therefore, lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in patients with newly diagnosed multiple myeloma. (Clinicaltrials.gov identifier NCT00405756)...
  9. doi request reprint The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leukemia 27:423-9. 2013
    ....
  10. doi request reprint Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Eur J Haematol 89:10-5. 2012
    ..These patients are often not included in clinical trials; thus, there is limited data on their characteristics and treatment outcome...
  11. doi request reprint A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Blood 119:2764-7. 2012
    ..In the context of the observed survival benefit in relapsed or refractory MM patients, the benefit/risk profile of lenalidomide/dexamethasone remains positive...
  12. doi request reprint The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Greece
    Ann Oncol 23:722-9. 2012
    ....
  13. pmc Non-blood medical care in gynecologic oncology: a review and update of blood conservation management schemes
    Maria Simou
    Department of Obstetrics and Gynecology, Alexandra Hospital, School of Medicine, University of Athens, Greece
    World J Surg Oncol 9:142. 2011
    ....
  14. pmc Treatment of early uterine sarcomas: disentangling adjuvant modalities
    Flora Zagouri
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, School of Medicine, Athens, Greece
    World J Surg Oncol 7:38. 2009
    ..However, more trials are needed to address these issues, especially, their sequential application. Patients with uterine sarcomas should be referred to large academic centers for participation in clinical trials...
  15. pmc Gestational trophoblastic neoplasia with retroperitoneal metastases: a fatal complication
    Nikolaos Thomakos
    Department of Clinical and Therapeutics, Alexandra Hospital, School of Medicine, University of Athens, Greece
    World J Surg Oncol 8:114. 2010
    ..The therapeutic approach of this condition includes both surgical intervention and chemotherapy. The prognosis depends on many prognostic factors that determine the stage of the disease...
  16. pmc Olive oil intake is inversely related to cancer prevalence: a systematic review and a meta-analysis of 13,800 patients and 23,340 controls in 19 observational studies
    Theodora Psaltopoulou
    Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, University of Athens, M Asias 75, Goudi, 11527, Athens, Greece
    Lipids Health Dis 10:127. 2011
    ..However, it is still unclear whether olive oil's monounsaturated fatty acid content or its antioxidant components are responsible for its beneficial effects...
  17. pmc Stauffer's syndrome as a prominent manifestation of renal cancer: a case report
    Georgios P Kranidiotis
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Alexandra Hospital, Athens, Greece
    Cases J 2:49. 2009
    ..abstract:..
  18. pmc A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study
    Christos A Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece
    BMC Med 9:10. 2011
    ..In this multicenter adjuvant phase III trial, we evaluated the addition of irinotecan to weekly 5FU plus LV in patients with stage II or III colon cancer...
  19. pmc Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group
    Aristotle Bamias
    Department of Clinical Therapeutics, Medical School, University of Athens, Athens, Greece
    BMC Cancer 6:228. 2006
    ..Surgery can cure a significant percentage of ovarian carcinoma confined to the pelvis. Nevertheless, there is still a 10-50% recurrence rate. We administered paclitaxel/carboplatin as adjuvant treatment in early-stage ovarian carcinoma...
  20. pmc Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model
    Aristotelis Bamias
    Department of Clinical Therapeutics, Athens University, Medical School, Athens, Greece
    BMC Cancer 10:45. 2010
    ..We studied the prognostic significance of baseline characteristics and we compared the risk stratification with the established Memorial Sloan Kettering Cancer Center (MSKCC) model...
  21. ncbi request reprint Treatment of AL amyloidosis with high dose therapy and autologous stem cell transplantation
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece
    Leuk Lymphoma 47:963-4. 2006
  22. ncbi request reprint Hematology: first-line bortezomib benefits patients with multiple myeloma
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Nat Rev Clin Oncol 6:683-5. 2009
    ....
  23. ncbi request reprint Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid
    Meletios A Dimopoulos
    Dept of Clinical Therapeutics, Medical School, University of Athens, Greece
    Haematologica 91:968-71. 2006
    ..0% and 5%, p=0.003). In conclusion, the risk of ONJ is increased with time of exposure and probably with the use of zoledronic acid...
  24. ncbi request reprint Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma
    Meletios A Dimopoulos
    Dept of Clinical Therapeutics, University of Athens School of Medicine
    Haematologica 91:252-4. 2006
    ..The median time to response was 2 months. The median time to progression for all patients was 21.2 months. Deep venous thrombosis and peripheral neuropathy each occurred in 9% of patients...
  25. ncbi request reprint Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, Euroclinic Hospital, Athens, Greece
    Haematologica 90:1655-8. 2005
    ..Thus, this agent is worth studying in patients with Waldenström's macroglobulinemia (WM)...
  26. ncbi request reprint Tandem autologous stem cell transplantation for multiple myeloma: is it applicable and effective outside clinical trials?
    Meletios A Dimopoulos
    Department of Clinical Therapeutics University of Athens School of Medicine, Athens, Greece
    Haematologica 90:1588. 2005
  27. ncbi request reprint Waldenström's macroglobulinemia
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, 227 Kifissias Avenue, 14561 Kifissia, Athens, Greece
    Best Pract Res Clin Haematol 18:747-65. 2005
    ..Patient's age, hemoglobin and serum beta2-microglobulin before treatment are important prognostic variables which correlate with survival...
  28. ncbi request reprint Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Greece
    J Clin Oncol 23:4381-9. 2005
    ..To quantitate the individual levels of melphalan-induced DNA damage formation and repair in vivo and to search for possible correlations with clinical outcome in patients with multiple myeloma (MM)...
  29. doi request reprint Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leukemia 24:1769-78. 2010
    ..The outcome of patients with del17p remains extremely poor even with VRD combination...
  30. ncbi request reprint Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Eur J Haematol 85:1-5. 2010
    ..Lenalidomide and dexamethasone (LenDex) is an active regimen for relapsed/refractory multiple myeloma (MM). However, there is limited data for the effect of LenDex on renal impairment (RI) and on renal reversibility...
  31. pmc The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
    Meletios Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
    Cancer 116:3807-14. 2010
    ....
  32. ncbi request reprint Bortezomib as a treatment option in patients with Waldenström macroglobulinemia
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, School of Medicine, Greece
    Clin Lymphoma Myeloma Leuk 10:110-7. 2010
    ..These encouraging data have led to the inclusion of bortezomib as a salvage treatment option in the recently updated Fourth International Workshop on Waldenström's Macroglobulinemia treatment recommendations...
  33. doi request reprint Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study
    Meletios A Dimopoulos
    School of Medicine, University of Athens, Athens, Greece
    Eur J Haematol 86:23-31. 2011
    ....
  34. ncbi request reprint Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis
    Meletios Athanasios Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leuk Lymphoma 47:1553-6. 2006
    ..087). With macrofocal MM despite multiple lytic bone lesions, patients have features of low tumor burden and improved survival when compared with young patients with typical MM...
  35. ncbi request reprint Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece
    Haematologica 92:1505-12. 2007
    ....
  36. doi request reprint Treatment of plasma cell dyscrasias with lenalidomide
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece
    Leukemia 22:1343-53. 2008
    ..In this review, we summarize the mechanisms of action, toxicity and clinical activity, and the current role of lenalidomide in patients with multiple myeloma or other related plasma cell disorders...
  37. doi request reprint Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
    M A Dimopoulos
    Department of Clinical Therapeutics, Medical School, University of Athens, Greece
    Ann Oncol 20:117-20. 2009
    ..We investigated whether the occurrence of ONJ decreased after the implementation of preventive measures in 128 patients with MM who received zoledronic acid...
  38. ncbi request reprint Treatment of Waldenstrom's Macroglobulinemia
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, 80 Vas Sofias, Athens, 11528, Greece
    Curr Treat Options Oncol 8:144-53. 2007
    ..For patients who develop resistance to all three classes of agents, alemtuzumab, thalidomide with or without dexamethasone or bortezomib could be tried...
  39. doi request reprint Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia
    Meletios Athanasios Dimopoulos
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Alexandra Hospital, Athens, Greece
    J Clin Oncol 27:120-6. 2009
    ..Finally, the panel reaffirmed its encouragement of the active enrollment of patients with WM onto innovative clinical trials whenever possible...
  40. doi request reprint Rituximab-based treatments in Waldenström's macroglobulinemia
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Clin Lymphoma Myeloma 9:59-61. 2009
    ..Rituximab has also been combined with thalidomide, which is an active and nonmyelosuppressive regimen. The rituximab-based combination represents today the most commonly used primary treatment for WM...
  41. doi request reprint International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma
    M Dimopoulos
    Department of Therapeutics, Alexandra Hospital, Athens, Greece
    Leukemia 23:1545-56. 2009
    ....
  42. doi request reprint Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leukemia 23:2147-52. 2009
    ..Low beta(2)-microglobulin and low bone marrow plasmacytosis were associated with longer survival. In conclusion, these data confirm the significant response and survival benefit with lenalidomide and dexamethasone...
  43. ncbi request reprint Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
    Clin Lymphoma Myeloma 9:302-6. 2009
    ..Bortezomib is active and well tolerated in patients with MM who present or develop renal impairment...
  44. ncbi request reprint Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leuk Lymphoma 47:2271-2. 2006
  45. ncbi request reprint Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Meletios Dimopoulos
    University of Athens School of Medicine, Athens, Greece
    N Engl J Med 357:2123-32. 2007
    ..This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma...
  46. doi request reprint VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, School of Medicine, Athens, Greece
    J Clin Oncol 27:6086-93. 2009
    ..CONCLUSION VMP is a feasible, active, and well-tolerated treatment option for previously untreated patients with MM with moderate renal impairment, resulting in 44% renal impairment reversal...
  47. ncbi request reprint High dose therapy for light chain amyloidosis: can we reduce treatment related mortality further?
    Meletios Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leuk Lymphoma 49:4-5. 2008
  48. ncbi request reprint Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Ann Oncol 14:1299-305. 2003
    ..Although several studies have evaluated possible prognostic factors of this disease, few have focused on the survival and prognosis of symptomatic patients after the initiation of treatment...
  49. doi request reprint Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
    Meletios Dimopoulos
    University of Athens, Athens, Greece
    Blood 117:4701-5. 2011
    ..The skeletal survey remains the standard method for imaging screening, but magnetic resonance imaging frequently provides valuable diagnostic and prognostic information. Most of these tests are repeated during follow-up or at relapse...
  50. ncbi request reprint Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study
    Christos A Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Athens, Greece
    Gynecol Oncol 92:152-9. 2004
    ..We conducted a phase II study using the combination of carboplatin and gemcitabine for the treatment of patients with relapsed platinum-sensitive and paclitaxel-pretreated EOC...
  51. doi request reprint Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
    Leukemia 25:749-60. 2011
    ..Ongoing trials will provide more insight into the effects of continuous lenalidomide-based therapy in myeloma...
  52. doi request reprint Tanespimycin as antitumor therapy
    Meletios Athanassios Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
    Clin Lymphoma Myeloma Leuk 11:17-22. 2011
    ..Like its parent compound geldanamycin, tanespimycin binds to HSP90 and causes antineoplastic effects in vitro and in vivo...
  53. ncbi request reprint Treatment of plasma cell dyscrasias with thalidomide and its derivatives
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    J Clin Oncol 21:4444-54. 2003
    ..In addition, preliminary results of phase I studies of the immunomodulatory derivatives (IMiDs) of thalidomide have been recently reported...
  54. pmc Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
    Leukemia 25:1620-6. 2011
    ..Thereafter, patients may benefit from lower-dose continued therapy; prospective studies are needed to confirm these findings...
  55. ncbi request reprint Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leuk Lymphoma 44:993-6. 2003
    ..We conclude that the FC combination appears to be active in patients with WM most of whom were resistant to treatment and had poor prognostic factors. The addition of rituximab to FC requires further investigation...
  56. ncbi request reprint Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics and Internal Medicine, University of Athens School of Medicine, Athens, Greece
    Ann Oncol 14:1039-44. 2003
    ..We designed a prospective randomized study to compare the objective response rates of two VAD-like outpatient regimens as primary treatment for symptomatic patients with multiple myeloma...
  57. ncbi request reprint Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group
    Meletios A Dimopoulos
    Department of Clinical Therapeutics and Radiotherapy, Alexandra Hospital, Athens, Greece
    Gynecol Oncol 85:476-82. 2002
    ..We administered a combination of these three agents to a large number of patients with metastatic or recurrent cervical cancer to evaluate its activity...
  58. ncbi request reprint High dose therapy with autologous stem cell transplantation for solitary bone plasmacytoma complicated by local relapse or isolated distant recurrence
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece
    Leuk Lymphoma 44:153-5. 2003
    ..All patients remain without evidence of disease for 4-10 years after the procedure. High dose therapy may be of value and require further study in patients with SBP who develop local or distant failure...
  59. ncbi request reprint Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, Theagenion Cancer Center, Greece
    Clin Lymphoma 3:163-6. 2002
    ..Studies that will combine rituximab with chemotherapy or with other monoclonal antibodies might be of interest...
  60. ncbi request reprint Solitary bone plasmacytoma and extramedullary plasmacytoma
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, 227 Kifissias Avenue, Kifissia, Athens 14561, Greece
    Curr Treat Options Oncol 3:255-9. 2002
    ..With more sensitive staging procedures, the diagnosis of SBP and SEP may become less common, but the number of patients with prolonged stability and cure may increase...
  61. ncbi request reprint Treatment of Waldenström's macroglobulinemia with rituximab
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Greece
    J Clin Oncol 20:2327-33. 2002
    ..There is evidence that patients with WM may benefit from treatment with the anti-CD20 monoclonal antibody rituximab. We performed a prospective phase II study to clearly define the activity of rituximab in patients with this disease...
  62. ncbi request reprint Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Greece
    Leuk Lymphoma 43:111-4. 2002
    ..Prospective randomized trials are needed in order to assess the impact of this treatment on patients' survival...
  63. ncbi request reprint Treatment of Waldenstrom's macroglobulinemia with thalidomide
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Greece
    J Clin Oncol 19:3596-601. 2001
    ..We performed a prospective phase II study to assess the activity of thalidomide in patients with Waldenstrom's macroglobulinemia (WM)...
  64. ncbi request reprint Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Hematol J 5:112-7. 2004
    ..Furthermore, it is not clear whether continuous administration of thalidomide is necessary for its antimyeloma effect. We performed a phase II study with a combination that was based on the intermittent administration of thalidomide...
  65. doi request reprint Renal insufficiency and failure
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Hematology Am Soc Hematol Educ Program 2010:431-6. 2010
    ..Lenalidomide, when administered at reduced doses according to renal function, is effective and can reverse renal impairment in a subset of myeloma patients...
  66. ncbi request reprint Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study
    Christos A Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Athens, Greece
    Oncology 66:112-7. 2004
    ..We conducted a phase II trial to evaluate the activity of oral letrozole in women with relapsed or recurrent epithelial ovarian cancer...
  67. ncbi request reprint How we treat Waldenström's macroglobulinemia
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Greece
    Haematologica 90:117-25. 2005
    ....
  68. ncbi request reprint Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Greece
    Leuk Lymphoma 45:2057-61. 2004
    ..We conclude that rituximab is an effective treatment modality for patients with WM. Patients with both low levels of monoclonal protein and normal albumin are the best candidates for treatment with standard dose rituximab...
  69. doi request reprint Multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Ann Oncol 21:vii143-50. 2010
    ..Maintenance therapy with thalidomide can be administered post-ASCT; however, caution is needed due to thalidomide toxicity...
  70. ncbi request reprint Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group
    Meletios A Dimopoulos
    University of Athens School of Medicine, Athens, Greece
    J Clin Oncol 28:4976-84. 2010
    ..High-dose melphalan (140 mg/m(2)) and autologous stem-cell transplantation should be limited to younger patients with chemosensitive disease...
  71. doi request reprint Emerging therapies for the treatment of relapsed or refractory multiple myeloma
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Eur J Haematol 86:1-15. 2011
    ..This review summarizes recent advances in understanding of the biology of relapsed/refractory MM and clinical trials with novel targeted agents that are currently under investigation for patients with this disease...
  72. ncbi request reprint Diagnosis and management of Waldenstrom's macroglobulinemia
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, 14561, Greece
    J Clin Oncol 23:1564-77. 2005
    ..To review the diagnostic criteria, prognostic factors, response criteria, and treatment options of patients with Waldenstrom's macroglobulinemia (WM)...
  73. doi request reprint Lenalidomide: an update on evidence from clinical trials
    Meletios Athanassios Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Blood Rev 24:S21-6. 2010
    ..Lenalidomide-based treatment is effective across the spectrum of MM disease phases, allowing for the long-term management of myeloma...
  74. ncbi request reprint Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, 227 Kifissias Avenue, Kifissia, Athens 14561, Greece
    Clin Lymphoma 5:270-2. 2005
    ..We conclude that patients with low levels of monoclonal protein and normal albumin are the best candidates for treatment with rituximab...
  75. ncbi request reprint The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia
    Meletios Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leuk Lymphoma 45:1809-13. 2004
    ..If this model is validated in independent series, it could provide a new staging system for WM based on readily available and reproducible variables...
  76. ncbi request reprint Adverse effects of thalidomide administration in patients with neoplastic diseases
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Am J Med 117:508-15. 2004
    ..Ongoing studies will clarify the potential advantages of these agents in the treatment of neoplastic diseases...
  77. ncbi request reprint Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors
    Athanasios Anagnostopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leuk Lymphoma 45:2275-9. 2004
    ..With the addition of performance status and serum LDH, a simple scoring system was developed which may help select patients likely to benefit from TBR...
  78. ncbi request reprint Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents
    Efstathios Kastritis
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, School of Medicine, Athens, Greece
    Haematologica 92:546-9. 2007
    ..046). In conclusion, RF is reversible in the majority of newly diagnosed MM patients treated with high-dose dexamethasone containing regimens. The addition of novel agents induces a more rapid RF reversal...
  79. ncbi request reprint Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome
    Eleni Efstathiou
    Department of Clinical Therapeutics, Athens University School of Medicine, Athens, Greece
    Anticancer Res 27:611-7. 2007
    ..The prognostic significance of age in ovarian cancer has not been clarified. We investigated the characteristics of ovarian cancer presenting in ages > 70 years and assessed the prognostic significance of advanced age...
  80. ncbi request reprint Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors
    Aristotle Bamias
    Department of Clinical Therapeutics, Medical School, University of Athens, Greece
    J Clin Oncol 23:8580-7. 2005
    ..We studied the incidence, characteristics, and risk factors for the development of ONJ among patients treated with bisphosphonates for bone metastases...
  81. ncbi request reprint Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents
    Maria Roussou
    Department of Clinical Therapeutics, University of Athens School of Medicine, 80 Vas Sofias, Athens 11528, Greece
    Leuk Res 34:1395-7. 2010
    ..Thus bortezomib-based regimens may be the preferred treatment for newly diagnosed myeloma patients with RI...
  82. doi request reprint Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid
    Giannis Mountzios
    Department of Medical Oncology, 251 General Airforce Hospital, University of Athens, Athens, Greece
    Transl Res 155:247-55. 2010
    ..003). None of the markers was able to predict skeletal morbidity or clinical outcomes independently of well-established prognostic clinical parameters...
  83. ncbi request reprint Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
    Evangelos Terpos
    Department of Haematology and Medical Research, General Airforce Hospital, Athens, Greece
    Br J Haematol 135:688-92. 2006
    ..This is the first study showing that bortezomib reduces DKK-1 and RANKL serum levels, leading to the normalisation of bone remodelling in relapsed myeloma...
  84. ncbi request reprint Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer
    G Aravantinos
    Hellenic Co operative Oncology Group, Athens, Greece
    Ann Oncol 14:1094-9. 2003
    ..This multicenter, prospective phase II study evaluated the safety and efficacy of the combination of docetaxel and vinorelbine in patients with platinum-resistant, paclitaxel-pretreated recurrent ovarian cancer...
  85. doi request reprint The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
    E Terpos
    Department of Hematology and Medical Research, 251 General Air Force Hospital, Athens, Greece
    Leukemia 22:2247-56. 2008
    ..We conclude that VMDT with intermittent thalidomide is an active and well-tolerated regimen for relapsed/refractory myeloma, affecting abnormal bone remodeling and angiogenesis...
  86. ncbi request reprint Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment
    E Efstathiou
    Department of Clinical Therapeutics, University of Athens School of Medicine, Haidari, Athens, Greece
    Urology 65:126-30. 2005
    ..In an effort to minimize toxicity, we designed an every-2-week docetaxel administration regimen with a 3-day low-dose EMP regimen. Patients with bone metastases also received zoledronic acid...
  87. ncbi request reprint Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenström macroglobulinaemia
    Evangelos Terpos
    Department of Haematology, General Airforce Hospital, Athens, Greece
    Br J Haematol 133:301-4. 2006
    ..These findings may explain the absence of lytic lesions in WM patients and suggest a potential role of MIP-1alpha in WM...
  88. doi request reprint Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patients
    Evangelos Terpos
    Department of Clinical Therapeutics, University of Athens School of Medicine, and Department of Hematopathology, Evangelismos General Hospital, Athens, Greece
    Clin Lymphoma Myeloma Leuk 11:115-7. 2011
    ..Our results support, for the first time in the literature, the production of CCL3 by WM cells. They also suggest a possible role of CCL3 in WM biology and reveal CCL3 as a potential target for developing novel drugs against WM...
  89. ncbi request reprint The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy
    E Kastritis
    University of Athens, Department of Clinical Therapeutics, Alexandra Hospital, 31 Komninon St, Haidari, 124 62, Athens, Greece
    Gynecol Oncol 104:372-6. 2007
    ..It is unknown whether these young patients have a poorer outcome compared to older patients or whether elderly patients have inferior outcome than younger patients when treated with combination chemotherapy...
  90. ncbi request reprint RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases
    Evangelos Terpos
    Alexandra University Hospital, University of Athens School of Medicine, Department of Clinical Therapeutics, 5 Marathonomahon Street, Drosia Attikis, 14572, Athens, Greece
    Expert Opin Biol Ther 9:465-79. 2009
    ..Osteoprotegerin (OPG) is the decoy receptor of RANKL. Disruption of the RANK/RANKL/OPG axis is implicated in bone metastases...
  91. ncbi request reprint Bortezomib in multiple myeloma
    Evangelos Terpos
    General Air Force Hospital, Department of Haematology and Medical Research, 3 Kanellopoulou Street, GR 11525, Athens, Greece
    Expert Opin Drug Metab Toxicol 4:639-54. 2008
    ..Bortezomib is a novel, first-in-class proteasome inhibitor that has improved outcomes in multiple myeloma, with manageable toxicities...
  92. doi request reprint Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
    E Kastritis
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece
    Leukemia 23:1152-7. 2009
    ..001). ISS was also valid in patients who actually received upfront treatment with novel drugs (4-year survival rate was 85, 61 and 26% for ISS stage I, II and III patients, P=0.001)...
  93. ncbi request reprint Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials
    C Bacoyiannis
    Medical Oncology Department, Hygeia Hospital, Athens, Greece
    Oncology 63:130-8. 2002
    ....
  94. ncbi request reprint Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus
    G T Bozas
    Department of Clinical Therapeutics, University of Athens, Alexandra Hospital, Greece
    Eur J Gynaecol Oncol 26:627-31. 2005
    ..The aim of this study was to investigate the activity and safety of paclitaxel/carboplatin chemotherapy as the only adjuvant treatment in patients with surgically resected UPSC and UCCC...
  95. ncbi request reprint Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy
    E Kastritis
    Department of Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Athens, Greece
    Int J Gynecol Cancer 16:994-9. 2006
    ..Patients with isolated brain metastases have comparable survival to patients with relapse outside the CNS, and long-term remission can be achieved in some cases, provided that systemic chemotherapy is added to local treatment...
  96. ncbi request reprint Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study
    G Aravantinos
    Agii Anargiri Cancer Hospital, Athens, Greece
    Ann Oncol 16:1116-22. 2005
    ..The two platinum derivatives have been previously combined as they are not totally cross-resistant and as they share no overlapping toxicities...
  97. ncbi request reprint Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG)
    G Papaxoinis
    Second Department of Internal Medicine, University General Hospital Attikon, University of Athens, Haidari, Greece
    Ann Oncol 19:780-6. 2008
    ..The aim was to examine characteristics and treatment results of patients with mucosa-associated lymphoid tissue (MALT) non-Hodgkin's lymphomas...
  98. ncbi request reprint Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study
    K Zervas
    Greek Myeloma Study Group, Athens, Greece
    Ann Oncol 15:134-8. 2004
    ....
  99. ncbi request reprint Thalidomide and dexamethasone combination for refractory multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Greece
    Ann Oncol 12:991-5. 2001
    ..We investigated the combination of thalidomide with dexamethasone as salvage treatment for heavily pretreated patients with multiple myeloma, in order to assess its efficacy and toxicity...
  100. ncbi request reprint The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio
    E Terpos
    Department of Hematology, 251 General Airforce Hospital, Athens, Greece
    Leukemia 19:1969-76. 2005
    ..These results suggest that the combination of intermediate dose of Thal/Dex is effective in patients with refractory/relapsed myeloma and improves abnormal bone remodeling through the reduction of sRANKL/OPG ratio...
  101. ncbi request reprint Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer
    G Aravantinos
    Hellenic Co operative Oncology Group, Athens, Greece
    Ann Oncol 11:607-12. 2000
    ..The prognosis of platinum resistant ovarian cancer is very poor and the treatment of choice has not been clearly defined...